How is EQ-5D data analysed in clinical trials? With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches. A must-read for trialists, health economists, and HTA professionals 👇

CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award. Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646) #CEA #HEOR

The EQ-5D has been commonly collected in many randomized clinical trials. However, it is not clear how it has been analyzed and reported. This systematic review focuses on how EQ-5D data were analyzed to estimate treatment effect in these trials. www.valueinhealthjournal.com/article/S109...

Exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases. www.healthaffairs.org/do/10.1377/f...

“The ‘new’ R&D ecosystem has given us some very effective drugs, but it has also become a machine converting money from patients, employers, and taxpayers into private wealth.” A brilliant, must-read piece if you are interested in drug pricing! www.healthaffairs.org/content/fore...